A Phase I/II, Open-Label, Safety, Pharmacokinetic, and Preliminary Efficacy Study of Oral Rucaparib in Patients With a Solid Tumor or With gBRCA Mutation Ovarian Cancer or Other Solid Tumor

Trial Profile

A Phase I/II, Open-Label, Safety, Pharmacokinetic, and Preliminary Efficacy Study of Oral Rucaparib in Patients With a Solid Tumor or With gBRCA Mutation Ovarian Cancer or Other Solid Tumor

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 19 Jun 2017

At a glance

  • Drugs Rucaparib (Primary)
  • Indications Advanced breast cancer; Carcinoma; Fallopian tube cancer; Lymphoma; Ovarian cancer; Peritoneal cancer; Solid tumours
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Acronyms Study 10
  • Sponsors Clovis Oncology
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 08 May 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Sep 2018.
    • 18 Mar 2017 Results of population pharmacokinetics of Rucaparib developed from A4991014 (n=35), NCT01482715 (n=124) and NCT01891344 (n=300) and 2 other studies, presented at the 118th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top